8-K
filed August 8, 2023, 7:59 PM ET
ticker TMCI
CIK 0001630627
earnings
confidence high
sentiment positive
materiality 0.75
Treace Medical Q2 revenue $42M (+40% YoY); raises FY guidance to $191-197M
TREACE MEDICAL CONCEPTS, INC.
2023-Q2 EPS reported
-$0.43
revenue$84,148,000
- Revenue $42.0M, up 40% YoY; gross margin 81.7% vs 82.3% last year.
- Net loss per share ($0.20) improved from ($0.31) YoY; adjusted EBITDA loss ($7.7M).
- FY2023 revenue guidance raised to $191-197M, representing 35-39% growth.
- Direct sales channel grew to 79% of sales; reached 200 quota-carrying sales reps.
- Completed acquisition of RedPoint Medical3D assets for patient-specific instrumentation.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
TREACE MEDICAL CONCEPTS, INC. reported quarter ended June 30, 2023 results: net income Second quarter net loss attributable to common stockholders was ($12.3) million, EPS ($0.20) per share. Guidance raised.
- Period
- quarter ended June 30, 2023
- Net income
- Second quarter net loss attributable to common stockholders was ($12.3) million
- EPS
- ($0.20) per share
- Guidance
- raised
- Result
- reported results
Exact text from the filing
Revenue of $42.0 million in the second quarter of 2023, a 40% increase over same period last year
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
TREACE MEDICAL CONCEPTS, INC. reported quarter ended June 30, 2023 results: net income Second quarter net loss attributable to common stockholders was ($12.3) million, EPS ($0.20) per share. Guidance raised.
- Period
- quarter ended June 30, 2023
- Net income
- Second quarter net loss attributable to common stockholders was ($12.3) million
- EPS
- ($0.20) per share
- Guidance
- raised
- Result
- reported results
Exact text from the filing
Second quarter net loss attributable to common stockholders was ($12.3) million, or ($0.20) per share, compared to ($17.2) million, or ($0.31) per share, for the same period of 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
TREACE MEDICAL CONCEPTS, INC. reported full-year 2023 results: revenue $191 million to $197 million. Guidance raised.
- Period
- full-year 2023
- Revenue
- $191 million to $197 million
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
Treace is raising its full-year 2023 revenue guidance to $191 million to $197 million, which represents approximately 35% to 39% growth over the Company’s 2022 revenue.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.